Addex Awarded Michael J. Fox Foundation Grant for ADX48621 to treat Levodopa-Induced Dyskinesia in Parkinson's Disease
SBA Member News, 09.09.2010

Allosteric modulation company Addex Pharmaceuticals Ltd (SIX:ADXN) announced today that it has been awarded a $900,000 grant from The Michael J. Fox Foundation (MJFF) to help fund a Phase II study of ADX48621 for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). more

Health Applicants Workshop
Berne, 09.09.2010 - 09.09.2010

Learn everything about submitting a strong proposal to FP7 Health more